Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL VALERATE versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL VALERATE versus STILPHOSTROL.
ESTRADIOL VALERATE vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol valerate is a prodrug of estradiol, a natural estrogen. Estrogens exert their effects by binding to estrogen receptors (ERα and ERβ), which act as transcription factors regulating gene expression. This leads to proliferation and growth of reproductive tissues, modulation of gonadotropin secretion, and effects on bone density, lipid metabolism, and other tissues.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
1-2 mg orally once daily adjusted based on response; for hormone therapy, 5-20 mg intramuscularly every 4 weeks.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 12-14 hours after intramuscular administration, allowing for weekly or biweekly dosing intervals.
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Renal (approximately 50% as glucuronide and sulfate conjugates), biliary/fecal (approximately 30-40% as conjugates), with enterohepatic circulation.
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category D/X
Category C
Estrogen
Estrogen